Incyte Corporation
INCY
Helyezés a részvények között
#1020
Incyte Corporation is a biopharmaceutical firm engaged in the research,... Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Részvényárfolyam
$113.55
Utolsó szinkronizálás: 2026-10-21
Piaci kapitalizáció
$23.02B
Változás (1 nap)
-2.63%
Változás (1 év)
28.94%
Ország
US
Kereskedés Incyte Corporation (INCY)
Kategória
Healthcare
Bevétel a(z) Incyte Corporation (INCY) részvényhez
Bevétel ekkor: Jun 2026 TTM: $5.82B
Incyte Corporation legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi árbevétele (TTM) $5.82B. 2024 évben a vállalat $4.24B árbevételt ért el, amely növekedés a 2023 évben elért $3.70B árbevételhez képest. Az árbevétel az a teljes összeg, amit a vállalat termékek vagy szolgáltatások eladásából generál. A nyereséggel ellentétben ebből nem vonódnak le költségek.
Incyte Corporation bevételtörténete 2000 és 2026 között
Bevétel az év végén
| Év | Bevétel | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $5.82B | 13.19% |
| 2025 | $5.14B | 21.22% |
| 2024 | $4.24B | 14.76% |
| 2023 | $3.70B | 8.87% |
| 2022 | $3.39B | 13.67% |
| 2021 | $2.99B | 11.98% |
| 2020 | $2.67B | 23.53% |
| 2019 | $2.16B | 14.71% |
| 2018 | $1.88B | 22.50% |
| 2017 | $1.54B | 38.93% |
| 2016 | $1.11B | 46.70% |
| 2015 | $753.75M | 47.36% |
| 2014 | $511.50M | 44.10% |
| 2013 | $354.95M | 19.49% |
| 2012 | $297.06M | 214.50% |
| 2011 | $94.46M | -44.40% |
| 2010 | $169.88M | 1,733.55% |
| 2009 | $9.27M | 136.41% |
| 2008 | $3.92M | -88.62% |
| 2007 | $34.44M | 24.59% |
| 2006 | $27.64M | 252.32% |
| 2005 | $7.85M | -44.54% |
| 2004 | $14.15M | -69.96% |
| 2003 | $47.09M | -53.66% |
| 2002 | $101.61M | -53.66% |
| 2001 | $219.26M | 12.92% |
| 2000 | $194.17M | 0.00% |
Hasonló cégek vagy versenytársak bevétele
| Vállalat | Bevétel | Bevételkülönbség | Ország |
|---|---|---|---|
| $12.62B | 116.93% |
US
|
|
| $2.23B | -61.72% |
US
|
|
| $15.74B | 170.54% |
AU
|
|
| $6.02B | 3.47% |
NL
|
|
| - | - |
CH
|
